Correlation of fasting serum apolipoprotein B-48 with coronary artery disease prevalence

European Journal of Clinical Investigation

Volumn 42, Issue 9, 2012, Pages 992-999

  Masuda, Daisaku ^a   Sugimoto, Taizo ^b   Tsujii, Ken ichi ^c   Inagaki, Miwako ^a   Nakatani, Kazuhiro ^a   Yuasa Kawase, Miyako ^a   Tsubakio Yamamoto, Kazumi ^a   Ohama, Tohru ^a,d   Nishida, Makoto ^a,d   Ishigami, Masato ^a   Kawamoto, Toshiharu ^e   Matsuyama, Akifumi ^f   Sakai, Naohiko ^g   Komuro, Issei ^a   Yamashita, Shizuya ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Sugimoto Clinic   (Japan)

^c Tsujii Clinic   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION   (Japan)

^f INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^g Sakai Clinic   (Japan)

Author keywords

Apolipoprotein B 48; Chylomicrons; Coronary artery disease; Postprandial hyperlipidemia; Remnant lipoproteins

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN B48; CHYLOMICRON; CHYLOMICRON REMNANT; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BODY MASS; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY RISK; FEMALE; GENDER; GLUCOSE METABOLISM; HUMAN; HYPERLIPIDEMIA; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; APOLIPOPROTEIN B-48; CORONARY ARTERY DISEASE; FASTING; FEMALE; HUMANS; HYPERGLYCEMIA; LIPIDS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PREVALENCE; RISK FACTORS; STATISTICS AS TOPIC;

EID: 84865177670     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2012.02687.x     Document Type: Article

References (30)

1. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population based prospective studies. J Cardiovasc Risk 1996;3:213-9.
2. Iso H, Naito Y, Sato S, Kitamura A, Okamura T, Sankai T et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol 2001;153:490-9.
3. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979;60:473-85.
4. Karpe F. Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med 1999;246:341-55.
5. Fujioka Y, Ishikawa Y. Remnant lipoprotein as strong key particles to atherogenesis. J Atheroscler Thromb 2009;16:145-54.
6. Kugiyama K, Doi H, Takazoe K, Kawano H, Soejima H, Mizuno Y et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 1999;99:2858-60.
7. Nakada Y, Kurosawa H, Tohyama J, Inoue Y, Ikewaki K. Increased remnant lipoprotein in patients with coronary artery disease; evaluation utilizing a newly developed remnant assay, remnant lipoproteins cholesterol homogenous assay (RemL-C). J Atheroscler Thromb 2007;14:56-64.
8. Sakai N, Uchida Y, Ohashi K, Hibuse T, Saika Y, Tomari Y et al. Measurement of fasting serum apoB-48 levels in normolipidemic and hyperlipidemic subjects by ELISA. J Lipid Res 2003;44:1256-62.
9. Kinoshita M, Ohnishi H, Maeda T, Yoshimura N, Takeoka Y, Yasuda D et al. Increased serum apolipoprotein B48 concentration in patients with metabolic syndrome. J Atheroscler Thromb 2009;16:517-22.
10. Meyer E, Westerveld HT, de Ruyter-Meijstek FC, van Greevenbroek MM, Rienks R, van Rijn HJ et al. Abnormal postprandial apolipoprotein B-48 and triglyceride responses in normolipidemic women with greater than 70% stenotic coronary artery disease: a case-control study. Atherosclerosis 1996;124:221-35.
11. Tanimura K, Nakajima Y, Nagao M, Ishizaki A, Kano T, Harada T et al. Association of serum apolipoprotein B48 level with the presence of carotid plaque in type 2 diabetes mellitus. Diabetes Res Clin Pract 2008;81:338-44.
12. Nakatani K, Sugimoto T, Masuda D, Okano R, Oya T, Monden Y et al. Serum apolipoprotein B-48 levels are correlated with carotid intima-media thickness in subjects with normal serum triglyceride levels. Atherosclerosis 2011;218:226-32.
13. Proctor SD, Mamo JC. Intimal retention of cholesterol derived from apolipoprotein B100- and apolipoprotein B48-containing lipoproteins in carotid arteries of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol 2003;23:1595-600.
14. Pal S, Semorine K, Watts GF, Mamo J. Identification of lipoproteins of intestinal origin in human atherosclerotic plaque. Clin Chem Lab Med 2003;41:792-5.
15. Nakano T, Nakajima K, Niimi M, Fujita MQ, Nakajima Y, Takeichi S et al. Detection of apolipoproteins B-48 and B-100 carrying particles in lipoprotein fractions extracted from human aortic atherosclerotic plaques in sudden cardiac death cases. Clin Chim Acta 2008;390:38-43.
16. Fujioka Y, Cooper AD, Fong LG. Multiple processes are involved in the uptake of chylomicron remnants by mouse peritoneal macrophages. J Lipid Res 1998;39:2339-49.
17. Valero R, Lorec AM, Paganelli F, Beliard S, Atlan C, Lairon D et al. Fasting apoprotein B-48 level and coronary artery disease in a population without frank fasting hypertriglyceridemia. Metabolism 2005;54:1442-7.
18. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K et al. Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 2007;14:155-8
19. Matsuzawa Y. Metabolic syndrome-definition and diagnostic criteria in Japan. J Jpn Soc Int Med (in Japanese) 2005;94:188-203.
20. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
21. Hanada H, Mugii S, Okubo M, Maeda I, Kuwayama K, Hidaka Y et al. Establishment of chemiluminescence enzyme immunoassay for apolipoprotein B-48 and its clinical applications for evaluation of impaired chylomicron remnant metabolism. Clin Chim Acta 2012;413:160-5.
22. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003;23:85-9.
23. Funada J, Sekiya M, Otani T, Watanabe K, Sato M, Akutsu H. The close relationship between postprandial remnant metabolism and insulin resistance. Atherosclerosis 2004;172:151-4.
24. Masuda D, Sakai N, Sugimoto T, Kitazume-Taneike R, Yamashita T, Kawase R et al. Fasting serum apolipoprotein B-48 level can be a marker of postprandial hyperlipidemia. J Atheroscler Thromb. 2011;18:1062-70.
25. Chan DC, Watts GF, Ng TW, Uchida Y, Sakai N, Yamashita S et al. Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism. Clin Chem 2005;51:578-85.
26. Chan DC, Watts GF, Ng TW, Yamashita S, Barrett PH. Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome. Eur J Clin Invest 2008;38:743-51.
27. Ishigami M, Yamashita S, Sakai N, Hirano K, Hiraoka H, Nakamura T et al. Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B-containing lipoproteins. Atherosclerosis 2003;168:359-66.
28. Westphal S, Wiens L, Güttler K, Dierkes J, Luley C. Chylomicron remnants of various sizes are lowered more effectively by fenofibrate than by atorvastatin in patients with combined hyperlipidemia. Atherosclerosis 2003;171:369-77.
29. Masuda D, Nakagawa-Toyama Y, Nakatani K, Inagaki M, Tsubakio-Yamamoto K, Sandoval JC et al. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Euro J Clin Invest 2009;39:689-98.
30. Sandoval JC, Nakagawa-Toyama Y, Masuda D, Tochino Y, Nakaoka H, Kawase R et al. Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia. J Atheroscler Thromb 2010;17:914-24.